Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer |
| |
Authors: | H Brincker MD H T Mouridsen MD K W Andersen statistician |
| |
Institution: | (1) Department of Oncology and Radiotherapy, Odense University Hospital, Copenhagen, Denmark;(2) The Finsen Institute, Copenhagen, Denmark;(3) Department of Oncology and Radiotherapy, Odense University Hospital, 5000 Odense C, Denmark |
| |
Abstract: | Summary After total mastectomy and partial axillary dissection, 805 premenopausal women with stage II breast cancer were randomized to receive postoperative radiotherapy (RT) alone, RT + cyclophosphamide (C) for 12 monthly cycles, or RT + cyclophosphamide/methotrexate/5-fluorouracil (CMF) for 12 monthly cycles. At 3 years actuarial relapse-free survival for RT + C and RT + CMF was significantly better than for RT alone (p = 0.0009 and 0.0001, respectively). There was no significant difference in relapse-free survival between RT + C and RT + CMF.C resulted in more pronounced haematologic toxicity and a higher frequency of amenorrhoea and of alopecia than CMF, while CMF resulted in more pronounced nausea and stomatitis than C.In the preliminary results, C alone may be as effective as CMF in prolonging relapse-free survival in premenopausal women with stage II breast cancer. |
| |
Keywords: | adjuvant therapy breast cancer CMF cyclophosphamide |
本文献已被 SpringerLink 等数据库收录! |
|